期刊文献+

氟西汀治疗32例难治性肠易激综合征近期疗效观察 被引量:1

Recent Effect of Fluoxetine on Patients with Refractory Irritable Bowel Syndrome
暂未订购
导出
摘要 目的观察氟西汀治疗难治性肠易激综合征(IBS)的近期疗效。方法按照罗马Ⅲ标准选择32例难治性腹泻型IBS患者,采用自身对照临床试验,给予氟西汀20mg/d,疗程12周,治疗过程中评定患者IBS主要症状评分、汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分。结果治疗后患者消化道主要症状评分、HAMD评分、HAMA评分均明显降低,差异有统计学意义(P<0.05),各观察指标呈逐周下降,按意图治疗(ITT)和方案分析(PP),治愈率分别为50.0%和51.6%,总有效率为分别96.8%和100.0%。结论心理因素在IBS的发病中起重要作用,氟西汀可显著改善难治性IBS患者的胃肠道症状及精神状态。 Objective To evaluate the recent efficacy of fluoxetine on the gastrointestinal and psychiatric symptoms in patients with refractory irritable bowel syndrome (IBS). Methods 32 patients with diarrheapredominant IBS symptoms according to the Rome Ⅲ criteria were treated with fluoxetine 20mg Qd for 12 weeks. The efficacy was evaluated by IBS gastrointestinal symptoms, abnormal frequency or consistency of defecation Hamilton depression scale (HAMD) and Hamilton anxiety scale (llAMA). Results 31 eases completed 12 weeks therapy, and the overall IBS symptoms, the Bristol stool consistency, stool frequency and abdominal pain were significantly relieved ( P 〈 0.05) ; there was obvious reduction for HAMD and HAMA and the difference was significant as compared to before treatment. The healing rate and total efficacy rate were 50.0% and 51.6% at intention-to-treat(ITT) analysis, and 96.8% and 100.0% at per-protocal(PP) analysis, respectively. Conclusion Psychological factors play an important role in the pathogenesis of IBS. Fluoxetine can significantly improve the psychiatric and gastrointestinal symptoms of refractory IBS patients.
出处 《咸宁学院学报(医学版)》 2009年第6期470-472,共3页 Journal of Xianning Univarsity(medical Sciences)
关键词 肠易激综合征 抗抑郁药 氟西汀 Irritable bowel syndrome Antidepressive agents Fluoxetine
  • 相关文献

参考文献6

  • 1刘新光.肠易激综合征与罗马Ⅲ诊断标准[J].胃肠病学,2006,11(12):736-738. 被引量:283
  • 2Bardhan KD, Bodemar G, C, eldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome [ J ]. Aliment Pharmacol Ther, 2000, 14 (1) :23.
  • 3Pae CU, Masand PS, Ajwani N. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review [ J ]. Int J Clin Pract,2007,61 (10) : 1708.
  • 4Videlock FJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment [ J ]. Castroenterol Clin North Am,2007,36(3) :665.
  • 5D Souza DL,Dimmitt DC,Robbins DK,et al. Effect of aloeetron on the pharmacokinetics of fluoxetine [ J ]. J Clin Phannacol,2001,41 (4) :455.
  • 6Dijkstra G,Van Coot H,Jansen PL, et al. Targeting nitric oxide in the gastrointestinal tract [ J ]. Curt Opin Investig Drugs ,2004 ,5 (5):529.

二级参考文献11

  • 1Drossman DA.Psychosocial and psychophysiologic mechanisms in GI Ⅲ ness.In:Kirsner JB,ed.The growth of gastroenterologic knowledge in the 20th century.Philadelphia:Lea & Febiger; 1993.41~432.
  • 2Whitehead WE,Palsson O,Jones KR.Systematic review of the comorbidity of irritable bowel syndrome with other disorders:what are the causes and implications? Gastroenterology,2002,122:1140~1156.
  • 3Drossman DA,Camilleri M,Mayer EA,Whitehead WE.AGA technical review on irritable bowel syndrome.Gastroenterology,2002,123:2108~2131.
  • 4Lea R,Whorwell PJ.New insights into the psychosocial aspects of irritable bowel syndrome.Curr Gastroenterol Rep,2003,5:343~350.
  • 5Drossman DA.The functional gastrointestinal disorders and the Rome Ⅲ process.Gastroenterology,2006,130:1377~1390.
  • 6Longstreth GF,Thompson WG,Chey WD,Houghton LA,Mearin F,Spiller RC.Functional bowel disorder.Gastroenterology,2006,130:1480~1491.
  • 7O'Donnell LJ,Virjee J,Heaton KW.Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.BMJ,1990,300:439~440.
  • 8Longstreth GF,Drossman DA.Severe irritable bowel and functional abdominal pain syndromes:managing the patient and health care costs.Clin Gastroenterol Hepatol,2005,3:397~400.
  • 9Chey WD,Chey WY,Heath AT,Dukes GE,Carter EG,Northcutt A,Ameen VZ.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Am J Gastroenterol,2004,99:2195~2203.
  • 10Muller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Loffier H.Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.Aliment Pharmacol Ther,2005,21:11~20.

共引文献282

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部